33 research outputs found
Prescription of dementia drugs from dementia clinics to patients according to specific diagnosis and gender.
<p>Prescription of dementia drugs from dementia clinics to patients according to specific diagnosis and gender.</p
Characteristics of the 1 347 564 older people, 2008.
<p>Characteristics of the 1 347 564 older people, 2008.</p
Follow-up group: Demographic data and follow-up responsibility.
<p>Follow-up group: Demographic data and follow-up responsibility.</p
Flow chart describing the patients included in the study.
<p>Flow chart describing the patients included in the study.</p
Dispensed dopaminergic and serotonergic drugs among 1 347 564 older people (≥65 years) according to age groups, 2008. Values are % (n).
<p>Dispensed dopaminergic and serotonergic drugs among 1 347 564 older people (≥65 years) according to age groups, 2008. Values are % (n).</p
Patients from study group included in follow-up group and response rates.
<p>Patients from study group included in follow-up group and response rates.</p
Combinations of dispensed dopaminergic and serotonergic drugs among 1 347 564 older people (≥65 years) according to age groups, 2008. Values are % (n).
<p>Combinations of dispensed dopaminergic and serotonergic drugs among 1 347 564 older people (≥65 years) according to age groups, 2008. Values are % (n).</p
Baseline data for patients from dementia clinics and prescribed dementia drugs.
<p>Baseline data for patients from dementia clinics and prescribed dementia drugs.</p
Basic characteristics of the study population according to APD<sup>a</sup> user status.
<p>Basic characteristics of the study population according to APD<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0161246#t001fn001" target="_blank"><sup>a</sup></a> user status.</p
Odds ratios with 95% confidence intervals for use of fall-risk inducing drugs in persons using APDs<sup>a</sup> compared to persons not using APD<sup>a</sup>.
<p>Odds ratios with 95% confidence intervals for use of fall-risk inducing drugs in persons using APDs<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0161246#t003fn001" target="_blank"><sup>a</sup></a> compared to persons not using APD<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0161246#t003fn001" target="_blank"><sup>a</sup></a>.</p